(19)
(11) EP 3 766 876 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.10.2023 Bulletin 2023/42

(45) Mention of the grant of the patent:
13.09.2023 Bulletin 2023/37

(21) Application number: 20191961.0

(22) Date of filing: 23.09.2009
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
C07D 401/02(2006.01)
A61K 31/47(2006.01)
A61P 33/02(2006.01)
 C07D 401/04(2006.01)
C07D 215/56(2006.01)
A61K 31/495(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 401/14; A61P 31/00; A61P 31/04; A61P 33/02

(54)

PHARMACEUTICAL FORMULATION CONTAINING A QUINOLONE DERIVATIVE

PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND CHINOLONVERBINDUNGEN

FORMULATIONS PHARMACEUTIQUES COMPRENANT DE COMPOSÉS DE QUINOLONE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
AL BA RS

(30) Priority: 24.09.2008 US 194083 P

(43) Date of publication of application:
20.01.2021 Bulletin 2021/03

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17163383.7 / 3214083
09816565.7 / 2346855

(73) Proprietor: Melinta Subsidiary Corp.
Parsippany, NJ 07054 (US)

(72) Inventors:
  • HANSELMANN, Roger
    Branford, CT 06405 (US)
  • REEVE, Maxwell M.
    Guilford, CT 06437 (US)
  • JOHNSON, Graham
    Madison, CT 06443 (US)

(74) Representative: Heller, Benjamin Henry et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)


(56) References cited: : 
WO-A1-2006/110815
 WO-A2-2006/015194
   
  • DAVID M BARNES ET AL: "Chlorination at the 8-Position of a Functionalized Quinolone and the Synthesis of Quinolone Antibiotic ABT-492", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, AMERICAN CHEMICAL SOCIETY, US, vol. 10, no. 4, 1 July 2006 (2006-07-01), pages 803-807, XP008146959, ISSN: 1083-6160, DOI: 10.1021/OP0600557 [retrieved on 2006-06-21]
  • ANTHONY R HAIGHT ET AL: "Synthesis of the Quinolone ABT-492: Crystallizations for Optimal Processing", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, AMERICAN CHEMICAL SOCIETY, US, vol. 10, no. 4, 1 July 2006 (2006-07-01), pages 751-756, XP008146957, ISSN: 1083-6160, DOI: 10.1021/OP060054E [retrieved on 2006-06-23]
  • ROGER HANSELMANN ET AL: "Identification and Suppression of a Dimer Impurity in the Development of Delafloxacin", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 13, no. 1, 16 January 2009 (2009-01-16), pages 54-59, XP055028113, ISSN: 1083-6160, DOI: 10.1021/op800238q
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).